Taussig Cancer Center, Center for Hematology and Oncology Molecular Therapeutics, Cleveland, Ohio, USA.
Gynecol Obstet Invest. 2010;70(1):23-33. doi: 10.1159/000279324. Epub 2010 Feb 2.
OBJECTIVE(S): To determine whether nuclear factor-kappaB (NF-kappaB) is constitutively and tumor necrosis factor (TNF)-dependently activated in endometriotic cells, whether trichostatin A (TSA) can suppress NF-kappaB activation and suppress TRAF2/6 and TAK1, and whether TSA and caffeic acid phenyl ester can suppress constitutive and H(2)O(2)-stimulated proliferation of endometriotic cells.
Two endometriotic cell lines and an endometrial stromal cell line were used as an in vitro model. Electrophoretic mobility shift analysis was used to determine NF-kappaB activation and possible suppression by TSA. Western blot analysis was used to determine whether TSA suppresses phosphorylation of IkappaBalpha, phosphorylation of p65 in the cytoplasm and nuclear translocation, and the expression of TRAF2/6 and TAK1.
NF-kappaB was constitutively activated in endometriotic cells, but only minimally in endometrial cells. TNFalpha stimulation activated NF-kappaB through induction of IkappaB phosphorylation, but the activation can be suppressed by TSA. TSA also attenuated constitutive and TNF-dependent p65 phosphorylation and nuclear translocation in endometriotic cells. TRAF2, TRAF6 and TAK1 were constitutively activated and were unaffected by TSA treatment.
NF-kappaB activation may play a critical role in the pathogenesis in endometriosis. Targeting NF-kappaB with histone deacetylase inhibitors or other compounds might hold promise as novel therapeutics for endometriosis.
确定核因子-κB(NF-κB)是否在子宫内膜异位症细胞中持续且依赖肿瘤坏死因子(TNF)激活,曲古抑菌素 A(TSA)是否能抑制 NF-κB 激活并抑制 TRAF2/6 和 TAK1,以及 TSA 和咖啡酸苯乙酯是否能抑制子宫内膜异位症细胞的固有和 H2O2 刺激增殖。
使用两种子宫内膜异位症细胞系和一种子宫内膜基质细胞系作为体外模型。电泳迁移率变动分析用于确定 NF-κB 的激活以及 TSA 可能的抑制作用。Western blot 分析用于确定 TSA 是否抑制 IkappaBalpha 的磷酸化、细胞质中 p65 的磷酸化和核转位以及 TRAF2/6 和 TAK1 的表达。
NF-κB 在子宫内膜异位症细胞中持续激活,但在子宫内膜细胞中仅轻微激活。TNFα刺激通过诱导 IkappaB 磷酸化激活 NF-κB,但 TSA 可抑制其激活。TSA 还减弱了子宫内膜异位症细胞中固有和 TNF 依赖性 p65 磷酸化和核转位。TRAF2、TRAF6 和 TAK1 持续激活,不受 TSA 处理的影响。
NF-κB 激活可能在子宫内膜异位症的发病机制中起关键作用。用组蛋白去乙酰化酶抑制剂或其他化合物靶向 NF-κB 可能是子宫内膜异位症的一种新的治疗方法。